Suppression of the humoral immune response by plasmacytomas: mediation by adherent mononuclear cells.

Systemic Mycobacterium kansasii infection and regulation of the alloantigenic response. Infect Immun (1981) 1.15

Use of a human plaque-forming cell assay to study peripheral blood bursa-equivalent cell activation and excessive suppressor cell activity in humoral immunodeficiency. J Clin Invest (1979) 1.11

Immunoregulatory T cell function in multiple myeloma. J Clin Invest (1981) 1.10

Nonspecific suppression of primary antibody responses and presence of plastic-adherent suppressor cells in Toxoplasma gondii-infected mice. Infect Immun (1981) 1.05

Immunosuppression in BALB/c mice bearing the plasmacytoma TEPC-183: massive increase in red pulp macrophages induced by the tumour. Immunology (1980) 0.99

The mode of action of splenic suppressor cells in murine plasmacytoma. Clin Exp Immunol (1981) 0.86

Suppressor activity of splenic macrophages in murine plasmacytoma (PC) is inhibited by PC specific ligands. Clin Exp Immunol (1982) 0.81

Nonspecific suppression of initiation of memory cells in Toxoplasma gondii-infected mice. Infect Immun (1981) 0.81

Suppression of in vitro antibody response by spleen cells of mice infected with Friend-associated lymphatic leukemia virus. Infect Immun (1979) 0.79

The role of T, B and adherent cells in the in vitro immune response of TEPC-183-bearing mice. Immunology (1982) 0.78

Diffusible suppressor factor from splenic macrophages in murine plasmacytoma. Clin Exp Immunol (1984) 0.78

An immunosuppressive lipoprotein fraction from TEPC-183 bearing mice. Clin Exp Immunol (1983) 0.75

Immunosuppression in plasmacytoma: induction of suppressor cells. Clin Exp Immunol (1982) 0.75

Effect of plant lectins on murine myeloma cells. Br J Exp Pathol (1979) 0.75

Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med (1982) 4.98

Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (1983) 4.72

Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72

Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol (1989) 4.07

Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol (1991) 3.93

Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol (1993) 3.39

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 3.33

Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 3.07

Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology (1995) 3.06

Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol (1994) 2.96

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1991) 2.85

Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol (1998) 2.83

Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J Virol (1997) 2.73

Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma. Am J Med (1982) 2.71

Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J Virol (2006) 2.13

Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med (1995) 2.12

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol (2006) 2.11

Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00

Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97

Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol (2000) 1.96

Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses (1992) 1.94

Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J Immunol (1997) 1.89

Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol (2000) 1.78

Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol (1998) 1.75

Pupil evaluation in addition to Glasgow Coma Scale components in prediction of traumatic brain injury and mortality. Br J Surg (2012) 1.73

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol (1990) 1.68

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64

Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med (1997) 1.62

Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology (1993) 1.60

Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol (1997) 1.59

Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol (1994) 1.57

Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology (1992) 1.56

Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses (1992) 1.53

Kaposi's sarcoma in homosexual men. A seroepidemiologic case-control study. Ann Intern Med (1984) 1.50

Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol (1998) 1.48

Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol (1997) 1.46

Human humoral responses to antigens of Mycobacterium tuberculosis: immunodominance of high-molecular-mass antigens. Clin Diagn Lab Immunol (1997) 1.43

Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J Virol (1998) 1.39

Serodiagnostic potential of culture filtrate antigens of Mycobacterium tuberculosis. Clin Diagn Lab Immunol (2000) 1.39

Delineation of human antibody responses to culture filtrate antigens of Mycobacterium tuberculosis. J Infect Dis (1998) 1.36

Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol (1993) 1.36

Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol (2001) 1.35

Surrogate marker of preclinical tuberculosis in human immunodeficiency virus infection: antibodies to an 88-kDa secreted antigen of Mycobacterium tuberculosis. J Infect Dis (1997) 1.35

Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol (1994) 1.35

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol (2000) 1.34

Quantitation of beta 2-microglobulin and other immune characteristics in a prospective study of men at risk for acquired immune deficiency syndrome. JAMA (1984) 1.32

Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc Natl Acad Sci U S A (1989) 1.31

Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins. Virology (2000) 1.29

Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J Virol (1998) 1.28

A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis (1999) 1.27

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses (1997) 1.26

Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1. J Virol (2001) 1.26

Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease. Proc Natl Acad Sci U S A (1987) 1.24

Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med (1988) 1.23

Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization. AIDS Res Hum Retroviruses (1998) 1.21

Nitric oxide production by human monocytes: evidence for a role of CD23. Immunol Today (1995) 1.20

Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J Virol (1998) 1.19

A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J Virol (2000) 1.19

A rapid, automated microtiter assay for measuring neutralization of HIV-1. AIDS Res Hum Retroviruses (1993) 1.18

B-cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters. Clin Exp Immunol (1988) 1.16

Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. Virology (1997) 1.16

Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J Infect Dis (1998) 1.15

Serum IgD elevation is an early marker of B cell activation during infection with the human immunodeficiency viruses. Clin Exp Immunol (1987) 1.14

Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. J Acquir Immune Defic Syndr (1994) 1.13

Splenic modifications induced by cyclophosphamide in C3H/He, nude, and "B" mice. J Immunol (1977) 1.12

Origin and function of suppressor macrophages in myeloma. J Immunol (1980) 1.12

AIDS: a syndrome of immune dysregulation, dysfunction, and deficiency. FASEB J (1989) 1.11

Immunosuppression and infection in multiple myeloma. Semin Oncol (1986) 1.10

Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades. J Virol (2001) 1.08

Passive immunization for the prevention and treatment of HIV infection. AIDS (1992) 1.08

Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120. J Virol (1993) 1.07

Molecular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response. Proc Natl Acad Sci U S A (1991) 1.07

A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. AIDS Res Hum Retroviruses (1998) 1.06

Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J Acquir Immune Defic Syndr (1993) 1.05

Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120. Immunol Lett (2001) 1.05

Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals. AIDS (1997) 1.02

Characterization by serial deletion competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies. Mol Immunol (1996) 1.01

Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology (1994) 0.99

Lamins A and C are not expressed at early stages of human lymphocyte differentiation. Exp Cell Res (1990) 0.99

A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J Virol (2000) 0.99

Cellular specificity of plasmacytoma-induced immunosuppression. J Immunol (1976) 0.98

Heterogeneous spontaneous and interleukin-4-induced nitric oxide production by human monocytes. J Leukoc Biol (1994) 0.96

Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity. Eur J Immunol (1992) 0.96

Four-year prospective study of homosexual men: correlation of immunologic abnormalities, clinical status, and serology to human immunodeficiency virus. J Infect Dis (1987) 0.95

Ligation of CD23 triggers cAMP generation and release of inflammatory mediators in human monocytes. J Immunol (1992) 0.94

Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. AIDS Res Hum Retroviruses (1997) 0.93

Epitopes of HIV-1 glycoproteins recognized by the human immune system. Chem Immunol (1993) 0.93

Enhancement of mouse natural killer cell activity by type II interferon. Ann Immunol (Paris) (1980) 0.93

Leukotriene B4 enhances IL-4-induced IgE production from normal human lymphocytes. Cell Immunol (1994) 0.92

The 25-kDa soluble CD23 activates type III constitutive nitric oxide-synthase activity via CD11b and CD11c expressed by human monocytes. J Immunol (1997) 0.92

Involvement of Fc epsilon RII/CD23 and L-arginine-dependent pathway in IgE-mediated stimulation of human monocyte functions. Int Immunol (1994) 0.92

Reinterpretation of human immunodeficiency virus western blot patterns. N Engl J Med (1989) 0.92

Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. AIDS Res Hum Retroviruses (1995) 0.92

Leukotriene B4 induces interleukin 5 generation from human T lymphocytes. Eur J Immunol (1993) 0.92

Purified excretory-secretory component of filarial parasite enhances Fc epsilon RII/CD23 expression on human splenic B and T cells and IgE synthesis while potentiating T-helper type 2-related cytokine generation from T cells. Immunology (1994) 0.91

Humoral immunity to HIV, SIV, and SHIV. AIDS (1998) 0.91

Regulation of ICAM-1/CD54 expression on human endothelial cells by hydrogen peroxide involves inducible NO synthase. J Leukoc Biol (2000) 0.91

Polymerase chain reaction-based assay for antibody-mediated neutralization of HIV-1 reveals a population of nonneutralized virus undetected by conventional p24 assay. J Acquir Immune Defic Syndr (2000) 0.91

The acquired immunodeficiency syndrome: an ultrastructural study. Hum Pathol (1985) 0.91

Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function. J Acquir Immune Defic Syndr (1990) 0.91